Advertisement
Policy Forum

Policy Forum Policy Forum articles provide a platform for health policy makers from around the world to discuss the challenges and opportunities in improving health care to their constituencies.

See all article types »

Disclosure of Investigators' Recruitment Performance in Multicenter Clinical Trials: A Further Step for Research Transparency

  • Rafael Dal-Ré mail,

    rfdalre@gmail.com; rdal-re@fpmaragall.org

    Affiliation: Early Detection Research Program, Alzheimer's Disease, Pasqual Maragall Foundation, Barcelona, Spain

    X
  • David Moher,

    Affiliation: Clinical Epidemiology Program, Ottawa Hospital Research Institute; Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada

    X
  • Christian Gluud,

    Affiliation: Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

    X
  • Shaun Treweek,

    Affiliation: Population Health Sciences, School of Medicine, University of Dundee and Tayside Clinical Trials Unit, Dundee, United Kingdom

    X
  • Jacques Demotes-Mainard,

    Affiliations: INSERM, Paris, France, European Clinical Research Infrastructures Network (ECRIN), Paris, France

    X
  • Xavier Carné

    Affiliation: Clinical Pharmacology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain

    X
  • Published: December 27, 2011
  • DOI: 10.1371/journal.pmed.1001149

About the Authors

Rafael Dal-Ré
Early Detection Research Program, Alzheimer's Disease, Pasqual Maragall Foundation, Barcelona, Spain
David Moher
Clinical Epidemiology Program, Ottawa Hospital Research Institute; Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada
Christian Gluud
Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Shaun Treweek
Population Health Sciences, School of Medicine, University of Dundee and Tayside Clinical Trials Unit, Dundee, United Kingdom
Jacques Demotes-Mainard
INSERM, Paris, France
Jacques Demotes-Mainard
European Clinical Research Infrastructures Network (ECRIN), Paris, France
Xavier Carné
Clinical Pharmacology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain

Corresponding Authors

Competing Interests

RDR reports being a GlaxoSmithKline employee (as Medical Director in Spain) until 2009 and owning stock in this firm. XC is the chairperson of the Spanish Commmittee of Drug Evaluation, an external advisory board to the Spanish Medicines Agency (AEMPS). DM is a member of the PLoS Medicine Editorial Board. The ideas and opinions expressed here are those of the authors and do not necessarily reflect those of the institutions or organizations they work for. All other authors reported having no competing interests.

Author Contributions

Wrote the first draft of the manuscript: RDR. Contributed to the writing of the manuscript: RDR DM CG ST JDM XC. ICMJE criteria for authorship read and met: RDR DM CG ST JDM XC. Agree with manuscript results and conclusions: RDR DM CG ST JDM XC. Involved in the critical revision of the manuscript for important intellectual content: RDR DM CG ST JDM XC.